Second, we suggest that plasma exosomal Aβ and tau may also serve as effective biomarkers for PD, particularly concerning cognitive function, because it has been shown that the annual changes in plasma EV tau and Aβ1-42 levels significantly differ between PD patients and healthy controls [27]. This evidence concerns the gene MAPT and Parkinson disease.